Hydrogel News and Research

RSS

FlexBone shows potential replacement for current bone transplantations

With a failure rate as high as 50 percent, bone tissue grafts pose a significant obstacle to orthopedic surgeons attempting to repair complex fractures or large areas of bone loss, such as those often caused by trauma and cancer. Current synthetic substitutes rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers at UMass Medical School have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone.

25 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

13 Oct 2010

NCKU develops novel stem cell therapy for heart repair

Assistant Prof. Patrick C. H. Hsieh of Institute of Nanotechnology and Microsystems Engineering, College of Medicine, National Cheng Kung University (NCKU), Tainan, Taiwan, has led a research team of myocardial regeneration to conduct an experiment on pigs and has proved that by combining self-assembling peptide nanofiber hydrogel with autologous bone marrow stem cell, myocardial protection after acute myocardial infarction, vascular regeneration and heart functions can be improved.

12 Oct 2010

Gelesis presents lead products data at Obesity 2010 Annual Meeting

Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.

11 Oct 2010

FDA clears Abbott's RevitaLens Ocutec contact lens disinfecting solution

Abbott has received U.S. Food and Drug Administration (FDA) market clearance for RevitaLens Ocutec™, a unique next-generation multi-purpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.

30 Sep 2010

DuPont and Royal DSM enter joint venture for advanced surgical biomedical materials

DuPont and Royal DSM N.V. announce an agreement to form a joint venture to develop, manufacture and commercialize advanced surgical biomedical materials, pending European Union regulatory approval. The joint venture will be named Actamax Surgical Materials LLC. Under the joint venture agreement, DuPont and DSM will each share a 50 percent interest.

23 Sep 2010

ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia

ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.

9 Sep 2010

Augmenix announces commercial implantation of SpaceOAR absorbable spacer system for radiation treatment

Augmenix, Inc. announced today that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company's CE Mark approved SpaceOAR System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues.

12 Aug 2010

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

These days people usually don't die from a heart attack. But the damage to heart muscle is irreversible, and most patients eventually succumb to congestive heart failure, the most common cause of death in developed countries.Stem cells now offer hope for achieving what the body can't do: mending broken hearts. Engineers and physicians at the University of Washington have built a scaffold that supports the growth and integration of stem cell-derived cardiac muscle cells. A description of the scaffold, which supports the growth of cardiac cells in the lab and encourages blood vessel growth in living animals, is published this week in the Proceedings of the National Academy of Sciences.

10 Aug 2010

CryoLife second-quarter revenues increase 4% to record $29.3 million

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.

30 Jul 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

20 Jul 2010

Implantable artificial salivary gland to be developed for Xerostomia patients

The goal of this research was to create an ECM modified hyaluronic acid (HA) based hydrogel culture system that allows for the growth and differentiation of salivary acinar cells into functional acini-like structures capable of secreting large amounts of protein and fluid unidirectionally. Xerostomia, a condition resulting from irradiation of the head and neck, affects more than 40,000 cancer patients each year in the United States. According to this research, these patients will greatly benefit from the development of a functional implantable artificial salivary gland.

15 Jul 2010

SurModics to present four scientific posters on drug delivery technologies at CRS Annual Meeting

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society, July 10-14, 2010 in Portland, Oregon (booth #521).

9 Jul 2010

Investment report on ULURU

MicroStockProfit.com announces an investment report featuring ULURU Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

22 Jun 2010

Report: Proper contact lens replacement schedule compliance associated with better vision, comfort

A report published in the journal Optometry & Vision Science demonstrated that patients who replaced their silicone hydrogel contact lenses according to the manufacturer recommended replacement frequency experienced better comfort and vision at the end of the day than non-compliant patients. The analysis was part of a larger study sponsored by CIBA VISION, which was developed to investigate contact lens replacement schedule compliance.

18 Jun 2010

Menicon announces acquisition of Lagado

Menicon Co., Ltd. announced on June 16 that Menicon and Lagado Corporation based in Colorado, USA, reached an agreement for Lagado to become a wholly owned subsidiary of Menicon America Inc., effective as of June 14, 2010.

16 Jun 2010

UH, AOA partner to get the word out about summer eye care, protection against UVR

As summer approaches, most people step up skin protection from harmful ultraviolet rays, yet aren't as vigilant about their eyes. Optometrists at the University of Houston are involved in a campaign to change this way of thinking.

15 Jun 2010

HyperBranch Medical Technology granted CE Mark for Adherus Spinal Sealant

HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for Adherus Spinal Sealant. Adherus Spinal Sealant is used in spinal surgeries where a water tight seal is required to prevent cerebrospinal fluid leakage from the dural repair. Prevention of cerebrospinal fluid leaks should benefit the patient in shorter hospital stays and fewer post-surgical complications such as reduced pain and fewer infections.